Skip to main content
ILLUMINA, INC. logo

ILLUMINA, INC. — Investor Relations & Filings

Ticker · ILMN ISIN · US4523271090 LEI · SQ95QG8SR5Q56LSNF682 US Manufacturing
Open in API
Filings indexed 2,572 across all filing types
Latest filing 2022-01-11 Call Transcript
Country US United States of America
Listing US ILMN

About ILLUMINA, INC.

https://www.illumina.com

Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company is a provider of DNA sequencing and array-based technologies. Its portfolio includes next-generation sequencing (NGS) platforms, microarrays, library preparation kits, and bioinformatics software. These products and services are utilized by researchers and clinicians for applications in life science research, translational and consumer genomics, molecular diagnostics, oncology, and reproductive health. The company's solutions are designed to advance genomic discoveries and enable precision medicine by providing tools for DNA, RNA, and protein analysis.

Recent filings

Filing Released Lang Actions
8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 10, 2022, by Illumina, Inc. It reports on the company's presentation at the J.P. Morgan Healthcare Conference where preliminary financial results for the fourth quarter and fiscal year ended January 2, 2022, were discussed. The document includes a transcript of the presentation as Exhibit 99.1 and reconciliations of non-GAAP financial measures. The key point is that the document is a transcript of a presentation, not the presentation slides themselves or a full report. The transcript is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition), which typically includes earnings-related information presented in calls or conferences. Given that this is a transcript of a conference presentation discussing financial results, the most appropriate classification is Call Transcript (CT). The document length is 4616 characters, which is consistent with a transcript rather than a full report. Therefore, the filing type code is CT with high confidence.
2022-01-11 English
PRIMARY DOCUMENT
Director's Dealing
2022-01-11 English
PRIMARY DOCUMENT
Director's Dealing
2021-12-30 English
PRIMARY DOCUMENT
Director's Dealing
2021-12-23 English
SC TO-I/A Filing
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 2 to Schedule TO, a Tender Offer Statement filed under the Securities Exchange Act of 1934. It reports the final results of an exchange offer by Illumina, Inc. to exchange contingent value rights for common stock or cash. The document includes details about the transaction valuation, filing fees, and the number of securities exchanged. It is a regulatory filing related to a tender offer, specifically reporting final results, not a full merger proxy statement or a detailed financial report. The document is about a tender offer and its results, which aligns with the category of Tender Offer Statements and related amendments. According to the provided filing categories, the closest match is 'Tender Offer Statement' filings, which fall under the category of Regulatory Filings (RNS) since there is no specific category for Schedule TO filings or tender offer statements in the list. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-12-21 English
PRIMARY DOCUMENT
Director's Dealing
2021-12-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.